Skip to content
preclinicalImmune & Inflammation

KE Dipeptide

Also known as: Lys-Glu, Lysine-Glutamic Acid Dipeptide, Vilon Analog, Khavinson KE Peptide

KE dipeptide (Lys-Glu) is an ultra-short synthetic dipeptide developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. It is the shortest known immunomodulatory peptide bioregulator, consisting of just two amino acids — lysine and glutamic acid. KE dipeptide is part of the Khavinson peptide bioregulator family (alongside Vilon, Epithalon, and others) and has been studied for thymus-targeted immune modulation, anti-aging effects, and potential geroprotective properties.

3 cited references·5 researched benefits

Quick Answer

KE dipeptide (Lys-Glu) is a synthetic two-amino-acid immunomodulatory peptide developed by Vladimir Khavinson as part of the Russian peptide bioregulator program. Despite its minimal size, it has demonstrated thymus-stimulating and immunomodulatory effects in preclinical research, promoting T-cell differentiation and restoring immune function in aging models. It represents the concept that even the shortest peptide sequences can carry biological signaling activity relevant to immune regulation and aging.

Key Facts

Mechanism
KE dipeptide is hypothesized to act through direct interaction with DNA and chromatin regulatory elements, consistent with the broader Khavinson peptide bioregulation theory. Research suggests it may bind to specific gene promoter sequences and influence transcription of genes involved in T-cell differentiation, thymic regeneration, and immune cytokine production. In preclinical models, KE dipeptide has been shown to promote thymocyte proliferation, enhance IL-2 and interferon-gamma production, and restore age-related declines in T-cell function. The exact molecular targets and receptor-mediated pathways remain under investigation.
Research Status
preclinical
Half-Life
~minutes (dipeptides are rapidly degraded by peptidases, but may exert epigenetic effects)
Molecular Formula
C₁₁H₂₁N₃O₅
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Stimulates thymocyte proliferation and T-cell differentiation in aging animal modelspreliminary
  • Restores age-related decline in IL-2 and interferon-gamma production in vitropreliminary
  • May promote thymic regeneration and reverse thymic involution in aged organismspreliminary
  • Ultra-short sequence allows oral bioavailability — potential for sublingual or oral dosingpreliminary
  • Part of the geroprotective peptide bioregulator class with potential anti-aging applicationsanecdotal

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral / Sublingual100–500 mcgDailyKhavinson peptide bioregulators are typically dosed orally or sublingually. Dipeptides may have sufficient oral bioavailability due to intestinal dipeptide transporters (PepT1).
Subcutaneous injection10–100 mcgDaily or every other dayParenteral administration used in some research protocols. Limited standardized human dosing data available.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Extremely well-tolerated in reported studies — no significant adverse effects documentedrare
  • Theoretical risk of immune overstimulation in autoimmune-prone individualsrare
  • Limited human safety data — most research is preclinicalrare

Frequently Asked Questions

How can a dipeptide have biological activity?
While it may seem unlikely that just two amino acids can produce meaningful biological effects, research has shown that even very short peptide sequences can interact with DNA, modulate gene expression, and trigger cellular signaling. The Khavinson school proposes that short peptides act as epigenetic regulators, binding to complementary DNA sequences and influencing transcription. Additionally, the PepT1 transporter in the gut can absorb dipeptides intact, providing a mechanism for oral bioavailability. However, it should be noted that much of this research comes from a limited number of research groups and awaits broader independent validation.
What is the relationship between KE dipeptide and Vilon?
Vilon (Lys-Glu or KE) is sometimes used interchangeably with KE dipeptide in the literature, though they may refer to slightly different preparations. Both are thymus-targeted Khavinson peptide bioregulators with the same Lys-Glu sequence. Vilon was originally isolated from thymic extract and the KE dipeptide represents its synthetic equivalent. They are part of the same family of ultra-short peptides studied for immunomodulation and anti-aging at the Saint Petersburg Institute of Bioregulation and Gerontology.
Is there strong clinical evidence for KE dipeptide?
The evidence for KE dipeptide remains largely preclinical, consisting primarily of in vitro cell culture studies and animal models from Russian research institutions. While the results are intriguing — showing thymic stimulation, immune cell activation, and potential geroprotective effects — independent replication by Western research groups is limited. No randomized controlled clinical trials in humans have been published in major international journals. Users should consider this a very early-stage research compound.

References

  1. 1
    Short peptides (Lys-Glu, Ala-Glu-Asp-Gly) regulate gene expression and protein synthesis during aging(2011)PubMed ↗
  2. 2
    Peptide geroprotectors — epigenetic regulators of aging and longevity: Khavinson peptide bioregulators(2014)PubMed ↗
  3. 3
    Molecular mechanisms of peptide bioregulation of gene expression during aging(2009)PubMed ↗

Latest Research

Last updated: 2026-02-19